Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.47 |
| ▸ | MAG | P20916 | 10/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077916 | 0.95 | MAG (0.45) | SIGLEC7MAGSELELGALS3LGALS1 | |
| SCHEMBL10077909 | 0.93 | SIGLEC7 (0.47) | SIGLEC7MAGSELELGALS3LGALS1 | |
| SCHEMBL10077906 | 0.92 | MAG (0.44) | SIGLEC7MAGSELELGALS3LGALS1 | |
| SCHEMBL10077912 | 0.92 | SIGLEC7 (0.48) | SIGLEC7MAGSELELGALS3LGALS1 | |
| SCHEMBL12130149 | 0.88 | SIGLEC7 (0.58) | SIGLEC7MAGSELE | |
| SCHEMBL10077910 | 0.87 | MAG (0.45) | SIGLEC7MAGSELELGALS3LGALS1 | |
| SCHEMBL17461353 | 0.87 | SIGLEC7 (0.53) | SIGLEC7MAGSELE | |
| SCHEMBL10077914 | 0.86 | MAG (0.46) | SIGLEC7MAGSELE | |
| SCHEMBL12130152 | 0.86 | SIGLEC7 (0.57) | SIGLEC7MAGSELE | |
| SCHEMBL4130437 | 0.85 | SIGLEC7 (0.48) | SIGLEC7MAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399656-B2 | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides | OTSUKA CHEMICAL CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120035345-A1 | PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035345-A1 | PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES | ASNS, BSG, ANPEP | SIGLEC7 13/4885MAG 974/4885SELE 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.